Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tCellVax
- Development stage
- Preclinical
- Lead developer
- Regen BioPharma
- Modality
- Bone Marrow HSCs → Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
tCellVax is a cell-based immunotherapy developed for the treatment of solid tumors. It works by extracting immune cells from a patient and using ex vivo siRNA technology to silence the NR2F6 gene in these cells. The silencing of NR2F6, an intracellular immune checkpoint, is intended to activate the patient's immune system against cancer. This approach aims to enhance anti-tumor immunity by removing inhibitory signals that limit T-cell activity. The therapy utilizes proprietary methods involving gene silencing through siRNA and may also incorporate modified mRNA technologies[1][2][3][4].
02
Targets
NR2F6 (Nuclear receptor subfamily 2 group F member 6)
Beyond the preview
Go deeper on tCellVax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tCellVax.